Intrathecal therapy for the management of cancer pain

Current Pain and Headache Reports

Volumn 10, Issue 4, 2006, Pages 254-259

  Brogan, Shane E ^a  

^a UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANALGESIC AGENT; ANTICOAGULANT AGENT; BACLOFEN; BUPIVACAINE; CAFFEINE; CLONIDINE; CREATINE KINASE; DROPERIDOL; FENTANYL; HYDROMORPHONE; KETAMINE; KETOROLAC; LOCAL ANESTHETIC AGENT; METHADONE; MIDAZOLAM; MORPHINE; MU OPIATE RECEPTOR; NEOSTIGMINE; OMEGA CONOTOXIN MVIIA; OPIATE; PETHIDINE; SODIUM CHANNEL BLOCKING AGENT; SUFENTANIL;

ANALGESIA; ANXIETY DISORDER; ATAXIA; AWARENESS; BACTEREMIA; BLOOD CLOTTING DISORDER; CANCER PAIN; CANCER RADIOTHERAPY; CATHETER INFECTION; CENTRAL NERVOUS SYSTEM; COGNITIVE DEFECT; COMPLEX REGIONAL PAIN SYNDROME; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; DELUSION; DOSE RESPONSE; DRUG ADMINISTRATION ROUTE; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG SAFETY; EDEMA; EQUIPMENT DESIGN; EVIDENCE BASED MEDICINE; EXTRAPYRAMIDAL SYMPTOM; FIBROSIS; FLUID THERAPY; FLUSHING; HEALTH CARE COST; HEARING DISORDER; HUMAN; HYPOTENSION; IMPLANTABLE PORT SYSTEM; INTERMETHOD COMPARISON; INTERNATIONAL NORMALIZED RATIO; KIDNEY DYSFUNCTION; LEUKOCYTE COUNT; MEDICAL DECISION MAKING; MENTAL DISEASE; MOTOR DYSFUNCTION; NAUSEA; ORTHOSTATIC HYPOTENSION; PAIN ASSESSMENT; PATHOPHYSIOLOGY; PATIENT CARE; POSTDURAL PUNCTURE HEADACHE; PRACTICE GUIDELINE; PRURITUS; RESPIRATION DEPRESSION; REST; RESTLESSNESS; REVIEW; SEPSIS; SIDE EFFECT; SKIN INFECTION; SOMNOLENCE; SYMPTOM; THROMBOCYTE COUNT; TREATMENT CONTRAINDICATION; TREATMENT INDICATION; TREATMENT OUTCOME; URINE RETENTION; VISUAL ANALOG SCALE;

ANALGESICS; DISEASE MANAGEMENT; DRUG DELIVERY SYSTEMS; HUMANS; INJECTIONS, SPINAL; NEOPLASMS; PAIN;

EID: 33746471217     PISSN: 15313433     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11916-006-0029-8     Document Type: Review

References (18)

1. Cleeland CS, Gonin R, Hatfield AK, et al.: Pain and its treatment in outpatients with metastatic cancer. N Engl J Med 1994, 330:592-596.
2. Vainio A, Auvinen A: Prevalence of symptoms among patients with advanced cancer: an international collaborative study. Symptom Prevalence Group. J Pain Symptom Manage 1996, 12:3-10.
3. Meuser T, Pietruck C, Radbruch L, et al.: Symptoms during cancer pain treatment following WHO-guidelines: a longitudinal follow-up study of symptom prevalence, severity, and etiology. Pain 2001, 93:247-257.
4. Smith TJ, Staats PS, Deer T, et al.: Randomized clinical trial of an implantable drug delivery system compared with comprehensive medical management for refractory cancer pain: impact on pain, drug-related toxicity, and survival. J Clin Oncol 2002, 20:4040-4049.
5. Baker L, Lee M, Regnard C, et al.: Evolving spinal analgesia practice in palliative care. Palliat Med 2004, 18:507-515.
6. Nitescu P, Hultman E, Appelgren L, et al.: Bacteriology, drug stability, and exchange of percutaneous delivery systems and antibacterial filters in long-term intrathecal infusion of opioid drugs and bupivacaine in "refractory" pain. Clin J Pain 1992, 8:324-337.
7. Bahar M, Rosen M, Vickers MD: Chronic cannulation of the intradural or extradural space in the rat. Br J Anaesth 1984, 56:405-410.
8. Crul BJ, Delhaas EM: Technical complications during long-term subarachnoid or epidural administration of morphine in terminally ill cancer patients: a review of 140 cases. Reg Anesth 1991, 16:209-213.
9. Bedder MD, Burchiel K, Larson A: Cost analysis of two implantable narcotic delivery systems. J Pain Symptom Manage 1991, 6:368-373.
10. Smith TJ, Coyne PJ, Staats PS, et al.: An implantable drug delivery system (IDDS) for refractory cancer pain provides sustained pain control, less drug-related toxicity, and possibly better survival compared with comprehensive medical management (CMM). Ann Oncol 2005, 16:825-833.
11. Stearns L, Boortz-Marx R, Du Pen S, et al.: Intrathecal drug delivery for the management of cancer pain: a multidisciplinary consensus of best clinical practices. J Support Oncol 2005, 3:399-408.
12. Eisenach J, Detweiler D, Hood D: Hemodynamic and analgesic actions of epidurally administered clonidine. Anesthesiology 1993, 78:277-287.
13. Ackerman LL, Follett KA, Rosenquist RW: Long-term outcomes during treatment of chronic pain with intrathecal clonidine or clonidine/opioid combinations. J Pain Symptom Manage 2003, 26:668-677.
14. Horlocker TT, Wedel DJ, Benzon H, et al.: Regional anesthesia in the anticoagulated patient: defining the risks (the second ASRA Consensus Conference on Neuraxial Anesthesia and Anticoagulation). Reg Anesth Pain Med 2003, 28:172-197.
15. Follett KA, Boortz-Marx RL, Drake JM, et al.: Prevention and management of intrathecal drug delivery and spinal cord stimulation system infections. Anesthesiology 2004, 100:1582-1594.
16. Coffey RJ, Burchiel K: Inflammatory mass lesions associated with intrathecal drug infusion catheters: report and observations on 41 patients. Neurosurgery 2002, 50:78-87.
17. Hassenbusch S, Burchiel K, Coffey RJ, et al.: Management of intrathecal catheter-tip inflammatory masses: a consensus statement. Pain Med 2002, 3:313-323.
18. Lossignol DA, Obiols-Portis M, Body JJ: Successful use of ketamine for intractable cancer pain. Support Care Cancer 2005, 13:188-193.